Growth Hormone Deficiency in Men: Signs and Treatment

Growth hormone deficiency affects approximately 1 in 10,000 adult men, causing significant fatigue, muscle loss, increased body fat, and mood changes. The condition occurs when the pituitary gland produces insufficient growth hormone, with levels typically falling below 3 ng/mL during stimulation testing. Common signs include a 20-30% reduction in muscle mass, 15-25% increase in abdominal fat, persistent fatigue, depression, and reduced bone density. Diagnosis requires specialized blood tests including IGF-1 levels and growth hormone stimulation tests performed by an endocrinologist. Treatment options include growth hormone replacement therapy, which costs $1,000-3,000 monthly as of 2026, or alternative approaches like peptide therapy using sermorelin or ipamorelin. Most men see improvements in energy and body composition within 3-6 months of treatment, though individual responses vary based on age and severity of deficiency.

Signs and Symptoms of Growth Hormone Deficiency

Growth hormone deficiency manifests through several distinct physical and psychological symptoms that develop gradually over months or years. Men with this condition typically experience a 20-30% reduction in lean muscle mass, particularly in the arms and legs, while abdominal fat increases by 15-25% even without changes in diet or exercise habits. The most common early symptoms include persistent fatigue that doesn't improve with rest, reduced exercise capacity, and difficulty building or maintaining muscle despite regular strength training. Many men also report mood changes, including increased irritability, anxiety, and depression. Sleep quality often deteriorates, with frequent nighttime awakenings and reduced deep sleep phases. Bone density decreases by 1-2% annually in untreated cases, leading to increased fracture risk. Skin thickness may reduce, and wound healing slows noticeably. Hair thinning and premature graying can occur, though these changes overlap with normal aging patterns.

Diagnostic Testing and Medical Evaluation

Diagnosing growth hormone deficiency requires specific blood tests that measure both IGF-1 levels and direct growth hormone response. IGF-1 (insulin-like growth factor 1) levels below 100 ng/mL in men over 40 suggest potential deficiency, though normal ranges vary by age and laboratory. The gold standard test involves growth hormone stimulation using arginine, L-DOPA, or insulin tolerance tests. A normal response shows growth hormone levels rising above 10 ng/mL, while deficient individuals typically peak below 3 ng/mL. These tests must be performed in clinical settings due to potential side effects. Your doctor will also evaluate other hormone levels, including testosterone, thyroid hormones, and cortisol, since deficiencies often occur together. Brain MRI may be recommended to rule out pituitary tumors or other structural abnormalities. Complete medical history and physical examination help distinguish growth hormone deficiency from other conditions causing similar symptoms.

Treatment Options and Expected Outcomes

Growth hormone replacement therapy remains the primary treatment, with synthetic human growth hormone administered through daily subcutaneous injections. Starting doses typically range from 0.2-0.3 mg daily, adjusted based on IGF-1 response and side effects. Treatment costs average $2,000-3,000 monthly in 2026, depending on dosage and insurance coverage. Peptide therapy offers alternative approaches with lower costs and fewer side effects. Sermorelin stimulates natural growth hormone production at doses of 0.2-0.3 mg daily, while ipamorelin provides more targeted stimulation with minimal impact on other hormones. These peptides cost $200-500 monthly and may be combined for enhanced effects. Most men notice initial improvements within 4-6 weeks, including better sleep quality and increased energy. Significant changes in body composition typically appear after 3-4 months of consistent treatment. Muscle mass increases by 10-15% and body fat decreases by 10-20% within the first year. Bone density improvements require 12-18 months of treatment. Regular monitoring includes quarterly IGF-1 levels, annual bone density scans, and periodic cardiovascular assessments. Some men also benefit from concurrent BPC-157 for enhanced recovery or TB-500 for tissue repair, particularly if starting an exercise program.

Frequently Asked Questions

Sources

1. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587-1609. PMID: 21602453
2. Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement. Front Endocrinol. 2013;4:64. PMID: 23761876
3. Johannsson G, Rosen T, Bosaeus I, et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1996;81(8):2865-2873. PMID: 8768842
4. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006;155(1):79-90. PMID: 16793953
5. Goetsch AL, Greenspan SL. Differential diagnosis of hypopituitarism in the elderly. Endocrinol Metab Clin North Am. 2005;34(4):1005-1019. PMID: 16310633
6. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. PMID: 18046910
7. Beck DE, Swanson JF, Jiang H, et al. The role of ipamorelin in the treatment of growth hormone deficiency. Curr Opin Endocrinol Diabetes Obes. 2007;14(4):318-323.
8. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of adult growth hormone deficiency with recombinant human growth hormone. Endocr Rev. 2000;21(6):681-696. PMID: 11133068